🔗 Share this article

While America proceeds with historic revisions to its immunization recommendations, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by questioning COVID-19 shots during the global health crisis and has focused upon possible deaths following COVID-19 vaccination in her recent position at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Vaccine Program

Health officials were set to announce radical revisions to the childhood vaccine schedule recently, aligning the US with Denmark’s vaccine program, according to reports – a major change that would put the US out of step with much of the global community with no evidence for benefit. The announcement has been delayed until the next year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this year.

A Shift at the FDA

The acting appointment could signify a closer partnership between the drug and biologics centers as Høeg and Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon reevaluating previously authorized immunizations at the FDA.

The new acting director has frequently advocated for halting specific childhood immunization guidelines in the US so as to align more like the Danish model, a nation with universal health coverage and a citizenry roughly the population of Wisconsin’s.

To date public appearances, she has kept her attention on immunizations – typically the purview of Dr. Prasad, head of the FDA’s vaccine center – rather than pharmaceutical oversight.

Questions Over Background

The appointee has no apparent experience in drug development, approval processes or administrative roles, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and CBER since March.

“She appears not to have the necessary background” for running the CDER, stated a neurologist and psychiatrist. “She’s never run a scientific study. She lacks experience in managing a sizeable institution. She is not an expert in industry regulation.”

Past directors of CBER would “understand laws and regulations and the underlying principles of medication creation”, commented Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who headed CBER have had.”

CDER has an enormous workload at the FDA, she stated.

“Many people just pays attention on the innovative therapies, but the generic drug division approves thousands of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and so forth, and each of these have to be supervised,” she explained. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a substantial management component to the job, which manages over 5,000 staff members. “It’s a enormous management job, if you execute it properly,” the former official concluded.

Response and Controversial Programs

In response to concerns about Høeg’s fitness for the role and whether this assignment indicates increased cooperation among FDA leaders on vaccines, a representative said that the “questions are based on flawed assumptions”.

“Her resume aligns with the functions of her role,” the spokesperson said, noting the time Dr. Høeg spent advising the agency head on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s recently launched priority voucher program, a contentious one-day medication authorization process that reportedly troubled her former heads. “By what process are these medications being selected for this expedited pathway? Who makes the calls?” Howard questioned. “There’s a lot of secrecy going on at the agency right now.”

Overall, he stated, “the agency appears to be shifting towards laxer rules of all drugs, aside from shots.”

Documented History on Immunizations

Regarding immunizations, Høeg has a more documented, if problematic, past, critics observe. She published a study using unconfirmed volunteer-provided data to assess the frequency of heart inflammation after COVID-19 vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are riskier than they are.

Among her “policy goals” for the new administration featured changing regulations for new vaccines and ending “optional” immunizations, she remarked after the election on a audio program. At the agency, Høeg has according to sources suggested barring adolescent males from getting Covid vaccinations.

“She is an thorough true believer who begins with her conclusions and tailors the evidence to fit the evidence in a highly disingenuous, dishonest way,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Høeg joined fellow contrarians, {like|